U.S. Building Stock News

What Dutch Bros stock’s recent performance tells you Dutch Bros (BROS) has traded softly in the short term, with a 2.2% one day move and a 3% decline over the past week, while still showing a positive return over the past 3 months. See our latest analysis for Dutch Bros. With the share price at US$61.14, Dutch Bros has seen short term share price pressure, but the 90 day share price return of 11.35% and 3 year total shareholder return of 79.82% point to longer term investors having been...

At CES 2026, Skyworks Solutions introduced the SKY66424-11, an integrated Wi-SUN/LoRaWAN RF front-end module for smart home and smart city uses, alongside new automotive-grade connectivity and e-mobility solutions. This push into advanced RF front-end, automotive GNSS, V2X and Bluetooth range extension highlights Skyworks’ effort to broaden beyond smartphones into infrastructure and transport connectivity. We’ll now examine how Skyworks’ push into Wi-SUN, LoRaWAN and automotive...

PG&E (PCG) has been drawing fresh attention after its recent share move, with the stock up about 3% over the past month even though its return over the past 3 months remains in negative territory. See our latest analysis for PG&E. At a share price of $15.78, PG&E’s 30 day share price return of 3.34% contrasts with its year to date share price return of a 3.01% decline and 1 year total shareholder return of a 6.15% decline, which together indicate that recent momentum has picked up relative to...

Clinical data and why it matters for Neurocrine Biosciences (NBIX) Neurocrine Biosciences (NBIX) put fresh clinical data for INGREZZA in front of investors, showing higher VMAT2 target occupancy and greater potency versus AUSTEDO XR at therapeutic doses, based on PET imaging in a head to head study. This kind of direct comparison in a recognized scientific setting can influence how physicians think about treatment choices for tardive dyskinesia and Huntington’s disease chorea. It can also...

PayPal Holdings (PYPL) has been under pressure recently, with the stock showing a 7% decline over the past month and a 16% decline over the past 3 months, prompting closer attention from investors. See our latest analysis for PayPal Holdings. Those short term share price declines sit against a weaker backdrop, with a year to date share price return of 2.4% and a 1 year total shareholder return of 36.04% in the red. This suggests momentum has been fading as investors reassess growth prospects...

If you are wondering whether Minerals Technologies at around US$67.64 is offering good value or not, you are asking the right question for this stock. The share price has moved by 3.8% over the last 7 days, 8.9% over the last 30 days and 10.6% year to date, while the 1 year return sits at a 9.8% decline and the 3 and 5 year returns are 6.5% and 5.6% respectively. Recent attention on Minerals Technologies has been driven by ongoing interest in materials names and how they are priced relative...

Why Recursion’s conference update is back on investors’ radar Recursion Pharmaceuticals (RXRX) is back in focus after its updated investor presentation at the J.P. Morgan Healthcare Conference highlighted early REC-4881 data in familial adenomatous polyposis and a cash runway the company expects to last through 2027. See our latest analysis for Recursion Pharmaceuticals. While the updated J.P. Morgan Healthcare Conference presentation and upcoming conference appearances have put Recursion...

Investors may be wondering if Vistra at around US$180 a share still offers value, or if most of the opportunity has already played out for new investors stepping in now. The stock has recently moved sharply, with a 19.6% return over the past 7 days, 3.9% over 30 days and a 9.0% return year to date, on top of a very large 3 year return and an 845.5% return over 5 years that may have changed how the market views its risk and reward profile. These moves sit against a backdrop of ongoing...

Nucor recently invited investors to a conference call held on January 27, 2026, where Chair, President and CEO Leon Topalian reviewed the company’s fourth quarter 2025 results and took questions on business conditions. Ahead of that call, Morgan Stanley shifted to a more cautious stance on Nucor, citing balanced risk-reward as softer steel demand could pressure pricing even as management pointed to stronger order backlogs in energy, infrastructure, data centers and manufacturing. Next, we’ll...

To understand whether Intel stock still offers value at today’s price, you need more than just a headline view. You need to see how its current market price lines up against different ways of estimating what the business might be worth. Intel’s share price recently closed at US$48.31, with returns of 17.5% over the last 7 days, 29.5% over the last 30 days, 22.7% year to date, 145.6% over 1 year, and 76.3% over 3 years, while the 5 year return sits at a 14.5% decline. This gives a mixed...

NXP Semiconductors and GE HealthCare announced a collaboration to apply secure, low-latency edge AI to anesthesia delivery and neonatal monitoring, showcasing hands-free operating-room controls and on-device infant safety alerts at CES 2026. This partnership underscores GE HealthCare’s push to embed responsible, explainable AI into medical workflows, potentially reshaping how clinicians interact with equipment in critical-care settings. We’ll now examine how the UBS downgrade, set against GE...

Texas Pacific Land (TPL) has drawn fresh attention after agreeing with Bolt Data & Energy to build large-scale data center campuses on its West Texas acreage, along with plans for a three-for-one stock split in December 2025. See our latest analysis for Texas Pacific Land. The recent data center plan and upcoming stock split arrive during a period of strong short term momentum, with a 30 day share price return of 20.97% and a 7 day gain of 9.24%. However, the 1 year total shareholder return...

Abbott Laboratories (ABT) is back in focus after unveiling Libre Assist, an AI driven feature within its Libre app at CES 2026. The new tool is aimed at helping U.S. diabetes patients anticipate food related glucose responses. See our latest analysis for Abbott Laboratories. Despite the buzz around Libre Assist and interest in upcoming earnings and the proposed Exact Sciences deal, Abbott's recent share price has been relatively soft, with a 90 day share price return showing a 3.9% decline...

In recent weeks, Heartland Advisors disclosed a new position in WESCO International and highlighted the distributor’s improving growth prospects and margin potential, while several Wall Street firms reiterated positive ratings. This combination of fresh institutional interest and broadly supportive analyst commentary has sharpened investor attention on WESCO’s operational efficiency and earnings trajectory. With WESCO’s shares advancing over the past week, we’ll examine how Heartland’s...

Bristow Group (VTOL) shares reacted to news that the company increased the size of its planned private offering of senior secured notes to $500 million. The proceeds are earmarked to refinance 2028 debt and support general corporate purposes. See our latest analysis for Bristow Group. The upsized notes offering comes at a time when momentum in Bristow Group’s share price has been firming, with a 30-day share price return of 12.81% and a year-to-date share price return of 9.67%. The 1-year...

If you are wondering whether Alibaba Group Holding's current share price reflects its true value, you are not alone. This article is built to help you frame that question clearly. The stock last closed at US$170.93, with returns of 10.7% over 7 days, 14.5% over 30 days, 9.8% year to date, 110.8% over 1 year and 54.3% over 3 years. The 5 year return sits at a 30.8% decline. Recent news around Alibaba has focused on its position as one of China's major e commerce and cloud players, alongside...

If you are wondering whether Arm Holdings' current share price lines up with its real worth, this article is built to walk you through that question step by step. Despite the hype around chip related names, Arm's share price closed at US$105.11, with returns of a 7% decline over 7 days, a 13.2% decline over 30 days, an 8.4% decline year to date, and a 28.7% decline over 1 year. This may change how investors think about both its growth potential and risk. Recent attention on Arm has largely...

Automatic Data Processing, Inc. previously declared a regular quarterly dividend of US$1.70 per share, payable on April 1, 2026, to shareholders of record as of March 13, 2026, and authorized a new US$6.00 billion share repurchase program replacing its prior authorization. This combination of a sizable buyback authorization and continued dividend payments underscores ADP’s emphasis on returning capital to shareholders alongside its recurring-revenue HR and payroll franchise. We’ll now...

If you are wondering whether Boeing's current share price still offers value after a strong run, this article walks through what the numbers actually say about the stock. Boeing shares recently closed at US$247.74, with reported returns of 9.0% over the past week, 19.8% over the past month, 8.8% year to date, 46.7% over the past year, 19.6% over three years, and 19.4% over five years. These moves have unfolded alongside ongoing headlines around the company and the wider aerospace and defense...

In recent days, AngloGold Ashanti has been highlighted by technical analysts for a perfect Technical Rating of 10 and strong setup quality, while benefitting from a broader rally in gold miners supported by robust cash flows and comparatively high dividend yields. This combination of constructive chart patterns and sector-wide strength in cash generation and payouts is drawing fresh attention to AngloGold Ashanti within the gold mining space. Next, we’ll examine how this constructive...

Why FormFactor’s recent earnings revisions are drawing attention FormFactor (FORM) is back on investor watchlists after analysts recently lifted full-year earnings estimates by 18.5%, while the stock has outpaced the broader Computer and Technology sector so far this year. See our latest analysis for FormFactor. The upbeat earnings revisions come on top of strong recent momentum, with a 30 day share price return of 34.48% and a 1 year total shareholder return of 74.18%. This suggests...

Protagonist Therapeutics: Recent Move After Strong Multi‑Year Returns Protagonist Therapeutics (PTGX) has drawn fresh attention after a strong 1 year total return of about 132%, set against more mixed shorter term moves, including a 7% decline over the past month. See our latest analysis for Protagonist Therapeutics. At a share price of $84.75, Protagonist Therapeutics has seen some momentum cool in the past month. Its 90 day share price return of 9.35% sits against a very large 3 year total...

In January 2026, MyPoint Credit Union announced it had partnered with Upstart to expand access to personal loans via the Upstart Referral Network, giving qualified Upstart.com applicants tailored MyPoint-branded offers and a streamlined digital application and closing process. This partnership, alongside rising attention on Upstart’s upcoming fourth-quarter and full-year 2025 results and ongoing credit-risk concerns, is sharpening focus on how its AI lending model balances growth, funding...

In early January 2026, a Montana federal judge allowed a class-action lawsuit over PFAS-laden firefighter turnout gear against 3M, DuPont/Chemours and others to proceed, rejecting multiple motions to dismiss, including RICO-related challenges. The ruling keeps RICO claims alive pending a Ninth Circuit decision and highlights potentially very large PFAS-related replacement costs for more than one million firefighters’ gear, adding to 3M’s legal and environmental risk profile. We’ll now...